1100 WINTER STREET, WALTHAM, MA
Reports Full Year 2025 Financial Results and Provides Business Updates
Investor Presentation
Announces Oversubscribed $50.0 Million Private Placement
Reports Third Quarter 2025 Financial Results and Provides Business Updates
Matthew Gall Appointed CFO of Kalaris Therapeutics, Effective Nov 3, 2025
Shareholder votes
Reports Second Quarter 2025 Financial Results and Provides Business Updates
Q3
Q2
Q1
FY 2024
FY 2023
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-4/A
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13D - Ownership Report
Schedule 13G - Ownership Report
SEC Staff Correspondence
Correspondence
Submission Upload